Three FDA-approved therapies for chronic GVHD.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014448
Abstract: Chronic graft-versus-host disease (cGVHD) is a major immunological complication of allogeneic hematopoietic cell transplantation. Chronic GVHD involves multiple organs, reduces quality of life and often requires prolonged therapy with glucocorticoids, causing severe side effects. After… read more here.
Keywords: approved therapies; fda approved; three fda; chronic gvhd ... See more keywords